Scans and Blood Tests in Melanoma Patients on Immunotherapy
Compares early PET/CT scans and blood tests in adults with advanced melanoma receiving immunotherapy.
Key facts
- Who runs it
- University of Wisconsin, Madison
- Where
- Madison, United StatesSee the site
- Trial code
- Registry title
- Correlating Early FDG PET/CT and ctDNA in Immune Checkpoint Inhibitor (ICI)-Treated Melanoma Patients
- Status
- Recruiting
- People taking part
- 24 people, planned
- Started
- 30 Jan 2024
- Expected to end
- Jan 2029
- Type of study
- Observational
- Treatments tested
- 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography
- Record updated
- 20 January 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced melanoma (stage III or IV) who are planning to start immune checkpoint inhibitor treatment and ctDNA blood monitoring.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Advanced stage III or stage IV melanoma, with treatment planned using ipilimumab, nivolumab, and/or pembrolizumab, alone or with other immune checkpoint inhibitor therapy
- Earlier treatment
- No investigational drugs, biologics, or devices within 30 days before joining
- Biomarker or test result
- Must plan to have Signatera™ (ctDNA level) monitoring with routine standard of care lab tests
Main reasons for not taking part
- Cannot receive immune checkpoint inhibitor therapy
- Used investigational drugs, biologics, or devices within 30 days before joining
- Pregnant, breastfeeding, or planning to become pregnant during the study
- Other reasons the investigators decide against joining
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Willing to provide informed consent
- Must have an advanced stage III or stage IV melanoma diagnosis for which treatment with ipilimumab, nivolumab, and/or pembrolizumab, either alone or in combination with other ICI therapy, is planned
- Must be planning to participate in Signatera™ (ctDNA level) monitoring with standard of care laboratory testing routinely obtained for treatment with ICI therapy
- Individuals at least 18 years of age
- Women of childbearing potential must be willing to use effective contraception as discussed with their oncologist while participating in this study
- Willing to comply with all study procedures and be available for the duration of the study
Who cannot take part
- Not able to receive treatment with ICI therapy
- Use of investigational drugs, biologics, or devices within 30 days prior to enrollment
- Women who are pregnant, lactating, or planning on becoming pregnant during the study
- Not suitable for study participation due to other reasons at the discretion of the investigators
Where in United States
- University of Wisconsin Hospitals and Clinics (UWHC)Madison, United StatesContact: Steve Cho, MD (principal investigator)Taking people
About the trial
What the trial wants to find out
The purpose of this research study is to determine if analysis of PET/CT scans and testing of blood samples in people with melanoma that has spread in their body can help researchers determine which patients are more or less likely to respond to immunotherapy and are more or less likely to have side effects. 24 participants will be enrolled and be on study until approximately 4 weeks after their first dose of Immune Checkpoint Inhibitor therapy.
The group in the trial
- Advanced Melanoma Patients with Immune Checkpoint Inhibitors
Treatment: 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Correlation Between Early Interval 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (PET/CT) and Circulating Tumor DNA (ctDNA) in Advanced Melanoma Patients Treated With Immune Checkpoint Inhibitors
- Plain-language title
- Scans and Blood Tests in Melanoma Patients on ImmunotherapyGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 20 January 2026